2015-06-24 | Set Price Target | HC Wainwright | Buy | $2.50 |
2015-06-23 | Downgrade | Roth Capital | Buy to Neutral | $4.65 to $1.65 |
2015-06-12 | Initiated Coverage | HC Wainwright | Buy | $2.50 |
2015-06-02 | Initiated Coverage | Roth Capital | Buy | $4.65 |
2012-09-21 | Initiated | Canaccord Genuity | Buy | $7 |
2009-06-12 | Initiated | Thomas Weisel | Overweight | $5 |
2008-11-25 | Initiated | Noble Financial | Buy | $5 |
2015-06-24 | Set Price Target | HC Wainwright | Buy | $2.50 |
2015-06-23 | Downgrade | Roth Capital | Buy to Neutral | $4.65 to $1.65 |
2015-06-12 | Initiated Coverage | HC Wainwright | Buy | $2.50 |
2015-06-02 | Initiated Coverage | Roth Capital | Buy | $4.65 |
2012-09-21 | Initiated | Canaccord Genuity | Buy | $7 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In VICL 0 funds of 2213 total. Show all
Fund name | Ticker shares |
---|
Name Relationship | Total Shares | Holding stocks |
---|---|---|
SINGER JAMES R | 9.79% (8670000) | VICL / |
ARMISTICE CAPITAL, LLC | 2.60% (2300000) | ALIM / VICL / |
BILINSKY IGOR Senior VP, Corporate Dev\'t | 0.22% (193798) | APHB / RXDX / VICL / |
Broadfoot Jill Marie Sr Vice President, CFO, Sec | 0.16% (145649) | VICL / |
ROLLAND ALAIN P PHD Exec VP, Product Development | 0.14% (127583) | VICL / |
MERTON ROBERT C | 0.11% (95451) | VICL / |
SAMANT VIJAY B President & CEO | 0.10% (87420) | APHB / RPTP / VICL / |
MORROW GEORGE J | 0.03% (27347) | ALGN / NBIX / OTIC / SWY / VICL / |
Beleson Richard M | 0.02% (22078) | VICL / |
SHERWIN STEPHEN A | 0.02% (22003) | BIIB / NBIX / RIGL / VICL / VSTM / |
SMITH LAWRENCE RUSSELL VP, Vaccine Research | 0.02% (17696) | VICL / |
LYONS GARY A | 0.02% (14906) | CYTX / KBIO / NBIX / PDLI / RIGL / TKAI / VICL / |
DOUGLAS R GORDON | 0.01% (10828) | VICL / |
SHENK THOMAS E | 0.01% (10000) | KDMN / VICL / |
Ramos Anthony Alan Chief Accounting Officer | 0.01% (9674) | VICL / |
CAMPBELL ROBERT H | 0.01% (6000) | VICL / |